TBK1 and glycogen storage disease VI: Furthermore, a study by Dan Li et al. reported a therapeutic role in animal disease models of IMIDs, including RA, SLE, psoriasis, and atopic dermatitis, using CS12192, a novel JAK3/JAK1/TBK1 inhibitor [82].